In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk.
Where this comes from
- Record sourced from PubMed, PMID 38048584.
- Also identified by DOI 10.7326/J23-0101.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. <b>Semaglutide in patients with heart failure with preserved ejection fraction and obesity.</b> N Engl J Med. 2023;389:1069-1084. 37622681.
Medical subject headings
- Heart Failure